Cargando…
Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
IMPORTANCE: COVID-19 disrupted delivery of buprenorphine and naltrexone treatment for opioid use disorder (OUD), and during the pandemic, members of racial and ethnic minority groups experienced increased COVID-19 and opioid overdose risks compared with White individuals. However, whether filled bup...
Autores principales: | Nguyen, Thuy, Ziedan, Engy, Simon, Kosali, Miles, Jennifer, Crystal, Stephen, Samples, Hillary, Gupta, Sumedha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161014/ https://www.ncbi.nlm.nih.gov/pubmed/35648400 http://dx.doi.org/10.1001/jamanetworkopen.2022.14765 |
Ejemplares similares
-
Racial and Ethnic Disparities in Prescription Coverage and Medication Use
por: Briesacher, Becky, et al.
Publicado: (2003) -
Early Racial and Ethnic Disparities in the Prescription of Nirmatrelvir for COVID-19
por: Tarabichi, Yasir, et al.
Publicado: (2023) -
Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access
por: Treitler, Peter, et al.
Publicado: (2023) -
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019) -
Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
por: Ruger, Jennifer Prah, et al.
Publicado: (2012)